112 related articles for article (PubMed ID: 3008768)
21. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
Mitsuya H; Weinhold KJ; Furman PA; St Clair MH; Lehrman SN; Gallo RC; Bolognesi D; Barry DW; Broder S
Proc Natl Acad Sci U S A; 1985 Oct; 82(20):7096-100. PubMed ID: 2413459
[TBL] [Abstract][Full Text] [Related]
22. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses.
Margolick JB; Volkman DJ; Folks TM; Fauci AS
J Immunol; 1987 Mar; 138(6):1719-23. PubMed ID: 3493285
[TBL] [Abstract][Full Text] [Related]
23. Tuberculosis--United States, 1985--and the possible impact of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection.
Centers for Disease Control (CDC)
MMWR Morb Mortal Wkly Rep; 1986 Feb; 35(5):74-6. PubMed ID: 3080659
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
Demirhan I; Chandra A; Sarin PS; Hasselmayer O; Hofmann D; Chandra P
Anticancer Res; 2000; 20(4):2513-7. PubMed ID: 10953320
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological inhibition of infectivity of HTLV-III in vitro.
Mitsuya H; Matsushita S; Harper ME; Broder S
Cancer Res; 1985 Sep; 45(9 Suppl):4583s-4587s. PubMed ID: 2990689
[TBL] [Abstract][Full Text] [Related]
26. Presence of HTLV-III in tears and cells from the eyes of AIDS patients.
Ablashi DV; Sturzenegger S; Hunter EA; Palestine AG; Fujikawa LS; Kim MK; Nussenblatt RB; Markham PD; Salahuddin SZ
J Exp Pathol; 1987; 3(4):693-703. PubMed ID: 3483881
[TBL] [Abstract][Full Text] [Related]
27. Natural killer activity from normal peripheral blood lymphocytes against a human T lymphotropic retrovirus type III (HTLV-III)-infected cell line.
Sirianni MC; De Sanctis G; Macchi B; Soddu S; Ensoli F; Aiuti F; Fontana L
Diagn Clin Immunol; 1988; 5(6):297-303. PubMed ID: 3219779
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of human T-lymphotropic leukemia virus type III associated with the acquired immunodeficiency syndrome.
Wong-Staal F; Hahn BH; Shaw GM; Arya SK; Harper M; Gonda M; Gilden R; Ratner L; Starcich B; Okamoto T
Princess Takamatsu Symp; 1984; 15():291-300. PubMed ID: 6100646
[TBL] [Abstract][Full Text] [Related]
29. Effects of D-penicillamine on human cell lines.
Baier-Bitterlich G; Schumacher W; Schulz TF; Wachter H; Dierich MP
Arzneimittelforschung; 1993 Mar; 43(3):395-8. PubMed ID: 8489573
[TBL] [Abstract][Full Text] [Related]
30. AIDS update: HTLV-III/LAV infection.
Cassens BJ
Pa Med; 1986 Jan; 89(1):24-6. PubMed ID: 3005945
[No Abstract] [Full Text] [Related]
31. [AIDS physiopathology and epidemiology of the infection with the LAV virus].
Gluckman JC
Rev Epidemiol Sante Publique; 1986; 34(2):112-7. PubMed ID: 3016830
[TBL] [Abstract][Full Text] [Related]
32. Substances affecting the infection and replication of human immunodeficiency virus (HIV).
Yamamoto N; Harada S; Nakashima H
AIDS Res; 1986 Dec; 2 Suppl 1():S183-9. PubMed ID: 3030346
[TBL] [Abstract][Full Text] [Related]
33. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.
Lifson JD; Feinberg MB; Reyes GR; Rabin L; Banapour B; Chakrabarti S; Moss B; Wong-Staal F; Steimer KS; Engleman EG
Nature; 1986 Oct 23-29; 323(6090):725-8. PubMed ID: 3095663
[TBL] [Abstract][Full Text] [Related]
34. Protection of T cells against infectivity and cytopathic effect of HTLV-III in vitro.
Mitsuya H; Matsushita S; Yarchoan R; Broder S
Princess Takamatsu Symp; 1984; 15():277-88. PubMed ID: 6085846
[TBL] [Abstract][Full Text] [Related]
35. HTLV-III: the etiologic agent of AIDS.
Sarngadharan MG; DeVico AL; Bruch L; Schüpbach J; Gallo RC
Princess Takamatsu Symp; 1984; 15():301-8. PubMed ID: 6100648
[TBL] [Abstract][Full Text] [Related]
36. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.
Harada S; Koyanagi Y; Yamamoto N
Science; 1985 Aug; 229(4713):563-6. PubMed ID: 2992081
[TBL] [Abstract][Full Text] [Related]
37. Acquired immune deficiency syndrome (AIDS)--recommendations of IMAP.
International Planned Parenthood Federation IPPF. International Medical Advisory Panel IMAP
IPPF Med Bull; 1986 Jun; 20(3):3-4. PubMed ID: 12268332
[TBL] [Abstract][Full Text] [Related]
38. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication.
Croen KD
J Clin Invest; 1993 Jun; 91(6):2446-52. PubMed ID: 8390481
[TBL] [Abstract][Full Text] [Related]
39. Analysis of human T-lymphotrophic virus sequences in multiple sclerosis tissue.
Hauser SL; Aubert C; Burks JS; Kerr C; Lyon-Caen O; de The G; Brahic M
Nature; 1986 Jul 10-16; 322(6075):176-7. PubMed ID: 3014351
[TBL] [Abstract][Full Text] [Related]
40. Human retroviral env and gag polypeptides: serologic assays to measure infection.
Kanner SB; Cheng-Mayer C; Geffin RB; Parks WP; Beltz GA; Arthur LO; Samuel KP; Papas TS
J Immunol; 1986 Jul; 137(2):674-8. PubMed ID: 3014000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
